trimetazidine has been researched along with n-formylmethionine leucyl-phenylalanine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrosio, G; Giraldez, R; Kuppusamy, P; Tritto, I; Wang, P; Zweier, JL | 1 |
1 other study(ies) available for trimetazidine and n-formylmethionine leucyl-phenylalanine
| Article | Year |
|---|---|
The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury.
Topics: Animals; Dose-Response Relationship, Drug; Female; Heart; Humans; In Vitro Techniques; Luminescent Measurements; Myocardial Reperfusion Injury; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Time Factors; Trimetazidine; Vasodilator Agents; Xanthine Oxidase | 2005 |